Immunomodulatory impact of interferon-alpha in combination with chemoradiation of pancreatic adenocarcinoma (CapRI)

[1]  K. Hess,et al.  Nuclear factor kappa B activation is a potential target for preventing pancreatic carcinoma by aspirin , 2005, Cancer.

[2]  A. Moretta.  The dialogue between human natural killer cells and dendritic cells. , 2005, Current opinion in immunology.

[3]  C. Craik,et al.  Selective chemical functional probes of granzymes A and B reveal granzyme B is a major effector of natural killer cell-mediated lysis of target cells. , 2005, Chemistry & biology.

[4]  H. Nakshatri,et al.  Parthenolide and sulindac cooperate to mediate growth suppression and inhibit the nuclear factor-κB pathway in pancreatic carcinoma cells , 2005, Molecular Cancer Therapeutics.

[5]  M. Büchler,et al.  Synergistic effects of interferon-alpha in combination with chemoradiation on human pancreatic adenocarcinoma. , 2005, World journal of gastroenterology.

[6]  Dolca Thomas,et al.  Distinct roles of IL-12 and IL-15 in human natural killer cell activation by dendritic cells from secondary lymphoid organs. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[7]  K. Tanabe,et al.  The role of Fas ligand and transforming growth factor β in tumor progression , 2004 .

[8]  Shadan Ali,et al.  Apoptosis-Inducing Effect of Chemotherapeutic Agents Is Potentiated by Soy Isoflavone Genistein, a Natural Inhibitor of NF-κB in BxPC-3 Pancreatic Cancer Cell Line , 2004, Pancreas.

[9]  Helen Hickey,et al.  A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. , 2004, The New England journal of medicine.

[10]  T. Sauerbruch,et al.  Intratumoral immunization with tumor RNA-pulsed dendritic cells confers antitumor immunity in a C57BL/6 pancreatic murine tumor model. , 2003, Cancer research.

[11]  Y. Kaneda,et al.  Inhibition of inducible NF-kappaB activity reduces chemoresistance to 5-fluorouracil in human stomach cancer cell line. , 2003, Experimental cell research.

[12]  D. Iannitti,et al.  Combined modality therapy for pancreatic cancer. , 2003, Seminars in oncology.

[13]  L. Qin,et al.  Mechanism of interferon alpha on inhibition of metastasis and angiogenesis of hepatocellular carcinoma after curative resection in nude mice , 2003, Journal of Gastrointestinal Surgery.

[14]  A. Hoos,et al.  Vaccination with heat shock protein–peptide complexes: from basic science to clinical applications , 2003, Expert review of vaccines.

[15]  A. Arlt,et al.  Role of NF-κB and Akt/PI3K in the resistance of pancreatic carcinoma cell lines against gemcitabine-induced cell death , 2003, Oncogene.

[16]  C. Bucana,et al.  Administration of optimal biological dose and schedule of interferon alpha combined with gemcitabine induces apoptosis in tumor-associated endothelial cells and reduces growth of human pancreatic carcinoma implanted orthotopically in nude mice. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[17]  L. Traverso,et al.  Interferon-based adjuvant chemoradiation therapy after pancreaticoduodenectomy for pancreatic adenocarcinoma. , 2003, American journal of surgery.

[18]  H. Kalthoff,et al.  Usage of the NF‐κB inhibitor sulfasalazine as sensitizing agent in combined chemotherapy of pancreatic cancer , 2003, International journal of cancer.

[19]  M. Gnant,et al.  In vivo induction of dendritic cell-mediated cytotoxicity against allogeneic pancreatic carcinoma cells. , 2003, International journal of oncology.

[20]  Marianne Fillet,et al.  NF-κB transcription factor induces drug resistance through MDR1 expression in cancer cells , 2003, Oncogene.

[21]  A. Arlt,et al.  NFkappaB-dependent chemoresistance in solid tumors. , 2002, International journal of clinical pharmacology and therapeutics.

[22]  John M. Kirkwood,et al.  Cancer immunotherapy: The interferon-α experience , 2002 .

[23]  S. Endres,et al.  Apoptotic Pancreatic Tumor Cells Are Superior to Cell Lysates in Promoting Cross-Priming of Cytotoxic T Cells and Activate NK and γδ T Cells , 2002 .

[24]  J. Kirkwood,et al.  Interferon-alpha in tumor immunity and immunotherapy. , 2002, Cytokine & growth factor reviews.

[25]  J. Trapani,et al.  CTL: Caspases Terminate Life, but that's not the whole story. , 2002, Tissue antigens.

[26]  J. Neoptolemos,et al.  New Techniques and Agents in the Adjuvant Therapy of Pancreatic Cancer , 2002, Acta oncologica.

[27]  M. Caligiuri,et al.  The biology of human natural killer-cell subsets. , 2001, Trends in immunology.

[28]  H. Kalthoff,et al.  CD95 and TRAIL receptor-mediated activation of protein kinase C and NF-κB contributes to apoptosis resistance in ductal pancreatic adenocarcinoma cells , 2001, Oncogene.

[29]  Jonathan W. Yewdell,et al.  Immunoproteasomes Shape Immunodominance Hierarchies of Antiviral Cd8+ T Cells at the Levels of T Cell Repertoire and Presentation of Viral Antigens , 2001, The Journal of experimental medicine.

[30]  K. Suk,et al.  IFNα sensitizes ME‐180 human cervical cancer cells to TNFα‐induced apoptosis by inhibiting cytoprotective NF‐κB activation , 2001 .

[31]  B. J. Van den Eynde,et al.  Differential processing of class-I-restricted epitopes by the standard proteasome and the immunoproteasome. , 2001, Current opinion in immunology.

[32]  S. Durum,et al.  Interferon–Alpha Suppresses the Antiapoptotic Effect of NF–kB and Sensitizes Renal Cell Carcinoma Cells in vitro to Chemotherapeutic Drugs , 2001, European Urology.

[33]  H. Kalthoff,et al.  Systemic and local immunosuppression in pancreatic cancer patients. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[34]  H. Kalthoff,et al.  Inhibition of NF-κB sensitizes human pancreatic carcinoma cells to apoptosis induced by etoposide (VP16) or doxorubicin , 2001, Oncogene.

[35]  J. Reboul,et al.  The type I interferon receptor: structure, function, and evolution of a family business. , 1999, Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research.

[36]  P. Koskinen,et al.  Interferon- Activates Multiple STAT Proteins and Upregulates Proliferation-Associated IL-2R, c-myc, and pim-1 Genes in Human T Cells , 1999 .

[37]  P. Marrack,et al.  Type I Interferons Keep Activated T Cells Alive , 1999, The Journal of experimental medicine.

[38]  A. N. Park,et al.  Interferon‐α and granulocyte‐macrophage colony‐stimulating factor differentiate peripheral blood monocytes into potent antigen‐presenting cells , 1998, Journal of leukocyte biology.

[39]  S Pestka,et al.  Biological properties of recombinant alpha-interferons: 40th anniversary of the discovery of interferons. , 1998, Cancer research.

[40]  M. Nausch,et al.  Immunohistochemical Characterization of the Pancreatic Cellular Infiltrate in Normal Pancreas, Chronic Pancreatitis and Pancreatic Carcinoma , 1998, Digestion.

[41]  G. Scambia,et al.  Interferons inhibit EGF-stimulated cell growth and reduce EGF binding in human breast cancer cells. , 1996, Anticancer research.

[42]  S. Yonehara,et al.  Concanamycin A, a powerful tool for characterization and estimation of contribution of perforin- and Fas-based lytic pathways in cell-mediated cytotoxicity. , 1996, Journal of immunology.

[43]  C. Janeway.  Immunobiology: The Immune System in Health and Disease , 1996 .

[44]  O. Colamonici,et al.  Cloning and Expression of a Long Form of the β Subunit of the Interferon αβ Receptor That Is Required for Signaling (*) , 1995, The Journal of Biological Chemistry.

[45]  R. Buller,et al.  Vaccinia Virus B18R Gene Encodes a Type I Interferon-binding Protein That Blocks Interferon α Transmembrane Signaling (*) , 1995, The Journal of Biological Chemistry.

[46]  J. Magae,et al.  Acidification is essential for maintaining the structure and function of lytic granules of CTL. Effect of concanamycin A, an inhibitor of vacuolar type H(+)-ATPase, on CTL-mediated cytotoxicity. , 1994, Journal of immunology.

[47]  J U Gutterman,et al.  Cytokine therapeutics: lessons from interferon alpha. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[48]  S. Mathur,et al.  Epstein Barr virus/complement C3d receptor is an interferon alpha receptor. , 1991, The EMBO journal.

[49]  K. Cantell,et al.  Enhancement of radiation effects by alpha interferon in the treatment of small cell carcinoma of the lung. , 1987, International journal of radiation oncology, biology, physics.

[50]  E. Gold,et al.  Epidemiology of pancreatic cancer , 1984, World Journal of Surgery.

[51]  F. Lynch.  The license to practice medicine , 1934 .

[52]  K. Tanabe,et al.  The role of Fas ligand and transforming growth factor beta in tumor progression: molecular mechanisms of immune privilege via Fas-mediated apoptosis and potential targets for cancer therapy. , 2004, Cancer.

[53]  M. Caligiuri,et al.  NK cell and DC interactions. , 2004, Trends in immunology.

[54]  M. Decatris,et al.  Potential of interferon-alpha in solid tumours: part 1. , 2002, BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy.

[55]  John Kirkwood,et al.  Cancer immunotherapy: the interferon-alpha experience. , 2002, Seminars in oncology.

[56]  S. Endres,et al.  Apoptotic pancreatic tumor cells are superior to cell lysates in promoting cross-priming of cytotoxic T cells and activate NK and gammadelta T cells. , 2002, Cancer research.

[57]  M. Probst-Kepper,et al.  Processing of some antigens by the standard proteasome but not by the immunoproteasome results in poor presentation by dendritic cells. , 2000, Immunity.

[58]  P. Koskinen,et al.  Interferon-alpha activates multiple STAT proteins and upregulates proliferation-associated IL-2Ralpha, c-myc, and pim-1 genes in human T cells. , 1999, Blood.